Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSLV-132 in Primary Sjögren's Syndrome
NCT06440525Phase 2Active, not recruiting
- Sponsor
- Resolve Therapeutics
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of RSLV-132 in primary Sjögren's syndrome, sponsored by Resolve Therapeutics. Started Dec 2024; status: active, not recruiting.
02
Drugs
RSLV-132
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06440525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440525.